for the ongoing Phase 2 clinical trial of GEO-CM04S1, GeoVax’s dual-antigen next-generation COVID-19 vaccine, as a booster vaccine for patients with chronic lymphocytic leukemia (CLL).

the available clinical data shed little light on its role in the treatment of CLL. Adverse effects include myelosuppression and gastrointestinal complaints. In a recent phase III trial of ...

If you’ve received a CLL diagnosis, you may want to consider participating in a clinical trial. CLL progression and severity can vary significantly from person to person, and clinical trials ...

Clinical trials have used various doses and treatment ... The dose administered to patients with CLL in the phase 3 trial was 100 mg/m 2 daily on 2 consecutive days every 28 days ( Table 1).

Grandad William Bennett, 69, was diagnosed with chronic lymphocytic leukaemia (CLL) 12 years ago, a type of blood cancer ...

Researchers at Dana-Farber Cancer Institute are presenting a promising advance in the treatment of chronic lymphocytic ...

Researchers found no significant differences in the risk of overall adverse events (AEs), but there were significant differences in grade 3 or higher AEs, serious AEs, treatment discontinuations due ...

Current treatments for patients with relapsed or refractory chronic lymphocytic leukemia have shown better outcomes than ...

Meaningful change thresholds for the EORTC Quality of Life Questionnaire in chronic lymphocytic leukemia (CLL) or small ...

This multiyear follow-up of more than 3300 patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) who ...

For patients with relapsed or refractory CLL, an expert explained that it’s important to understand the order of how ...

Susan L. Slager, PhD, discusses the background of her research on inherited germline genetics for risk of chronic lymphocytic ...